{
    "url_original": "https://www.wsj.com/articles/pfizer-licenses-promising-covid-19-pill-to-u-n-backed-nonprofit-11637063101?mod=business_lead_pos3",
    "url": "pfizer-licenses-promising-covid-19-pill-to-u-n-backed-nonprofit-11637063101",
    "title": "Pfizer Licenses Promising Covid-19 Pill to U.N.-Backed Nonprofit",
    "sub_head": "Manufacturing agreement is second by Medicines Patent Pool aiming to boost supplies of pill to prevent infections from turning severe",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-435575?width=860&height=573",
    "image_1": "im-435575.jpg",
    "time": "2021-11-16 06:45:00",
    "body": "Pfizer Inc.  is licensing its experimental Covid-19 antiviral to a global health organization in an effort to make the pill more readily available to people in low- and middle-income countries.<br />Under the licensing agreement, the United Nations-backed Medicines Patent Pool will work with other drugmakers to manufacture the pill for use in 95 countries, including in sub-Saharan Africa, Pfizer and the nonprofit said Tuesday."
}